Show simple item record

dc.contributor.authorGansmo, Liv Beathe
dc.contributor.authorRomundstad, Pål Richard
dc.contributor.authorBirkeland, Einar Elvbakken
dc.contributor.authorHveem, Kristian
dc.contributor.authorVatten, Lars Johan
dc.contributor.authorKnappskog, Stian
dc.contributor.authorLønning, Per Eystein
dc.date.accessioned2016-03-08T11:15:45Z
dc.date.accessioned2016-05-11T08:37:10Z
dc.date.available2016-03-08T11:15:45Z
dc.date.available2016-05-11T08:37:10Z
dc.date.issued2015-10-16
dc.identifier.citationCancer Medicine 2015, 4(12):1901-1907nb_NO
dc.identifier.issn2045-7634
dc.identifier.urihttp://hdl.handle.net/11250/2388996
dc.description.abstractThe MDM4 protein plays an important part in the negative regulation of the tumor suppressor p53 through its interaction with MDM2. In line with this, MDM4 amplification has been observed in several tumor forms. A polymorphism (rs4245739 A>C; SNP34091) in the MDM4 3′ untranslated region has been reported to create a target site for hsa-miR- 191, resulting in decreased MDM4 mRNA levels. In this population-based case–control study, we examined the potential association between MDM4 SNP34091, alone and in combination with the MDM2 SNP309T>G (rs2279744), and the risk of breast-, colon-, lung-, and prostate cancer in Norway. SNP34091 was genotyped in 7,079 cancer patients as well as in 3,747 gender-and age-matched healthy controls. MDM4 SNP34091C was not associated with risk for any of the tumor forms examined, except for a marginally significant association with reduced risk for breast cancer in a recessive model (OR = 0.77: 95% CI = 0.59–0.99). Stratifying according to MDM2 SNP309 status, we observed a reduced risk for breast cancer related to MDM4 SNP34091CC among individuals harboring the MDM2 SNP309GG genotype (OR = 0.41; 95% CI = 0.21–0.82). We conclude, MDM4 SNP34091 status to be associated with reduced risk of breast cancer, in particular in individuals carrying the MDM2 SNP309GG genotype, but not to be associated with either lung-, colon-or prostate cancer.nb_NO
dc.language.isoengnb_NO
dc.publisherWiley Open Accessnb_NO
dc.relation.urihttp://onlinelibrary.wiley.com/doi/10.1002/cam4.555/epdf
dc.rightsNavngivelse 3.0 Norge*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/no/*
dc.titleMDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung- and prostate cancer risk.nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.date.updated2016-03-08T11:15:45Z
dc.source.pagenumber1901-1907nb_NO
dc.source.volume4nb_NO
dc.source.journalCancer Medicinenb_NO
dc.source.issue12nb_NO
dc.identifier.doi10.1002/cam4.555
dc.identifier.cristin1340513
dc.description.localcode© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.nb_NO


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 3.0 Norge
Except where otherwise noted, this item's license is described as Navngivelse 3.0 Norge